MADISON, Wis., June 26, 2019 /PRNewswire/ -- Less than 20 months after breaking ground, Exact Sciences today opened the doors on its new, 169,000 square foot clinical laboratory and warehouse on the City of Madison's near west side.
Exact Sciences is a biotechnology company focused on delivering life-changing innovations in earlier cancer detection. The laboratory opened Wednesday will process Cologuard, the company's colorectal cancer screening test. The new facility is expected to help bring the company's total Cologuard processing capacity to 7 million tests per year, and unites many core business functions within a common campus.
"Madison, Wisconsin is the home of earlier cancer detection," said Exact Sciences president and CEO, Kevin Conroy. "From this campus, our Laboratory and Customer Care teams will help people across the country get screened and detect colorectal cancers and precancers. This will help improve outcomes, change lives, and reduce the toll colorectal cancer takes on our society."
Following a ceremonial ribbon cutting, guests toured the new lab to learn about the DNA analysis and processes which produce a Cologuard result.
"What we are doing is extremely high tech, and it is also extremely accessible," said Ana Hooker, senior vice president of Operations for Exact Sciences. "We want everyone who visits this lab to understand the science behind our process and the rigor and care applied at each step."
Campus supports growing teams
The new facility reflects the company's continued expansion and growth. In 2009, Exact Sciences relocated its headquarters to Madison, Wisconsin and restarted operations. At the time, it employed a handful of employees. Today, Exact Sciences employs more than 2,300 people, with three-quarters of its workforce in Wisconsin. The company currently has more than 300 open positions.
The company expects the number of health care providers and patients choosing Cologuard to continue to increase. Exact Sciences is investing in its clinical laboratory facilities and professionals. By the end of 2019, Exact Sciences expects to have the laboratory capacity to process up to 7 million Cologuard tests per year, which consists of 4 million tests per year at the lab opened today and 3 million per year at its existing lab.
"More than 30 million Americans are not current with colorectal cancer screening guidelines," said Mark Stenhouse, president of Exact Sciences' Cologuard business. "We designed Cologuard to help people get screened, and it is doing exactly that. Approximately half of all new Cologuard users were previously unscreened. This lab is a milestone in our company's ongoing efforts to change stagnant screening rates and help people take control of their health."
Since Cologuard received FDA approval in 2014, Exact Sciences processed more than 2 million Cologuard results – one million in the last year alone.
The lab opening took place at what Exact Sciences is calling its Discovery Campus. The company acquired the property in November 2017 and immediately broke ground on the lab and warehouse facilities.
Next to the lab, the Exact Sciences Customer Care team resides in a newly renovated office building on the campus. A 970-stall parking garage opens at the end of the month, and construction is underway on a cafeteria and employee amenities building, linking the lab to the office building. Production and manufacturing space adjacent to the lab will also soon come online to support Cologuard's anticipated growth.
The growth is producing demand for new talent, across a wide variety of job types and experience levels. Exact Sciences and Urban League of Greater Madison (ULGM) operate training academies which expose jobseekers and those considering a career change to opportunities within the biotech company's lab and customer care teams.
"You don't have to be a scientist to work at Exact Sciences," said Ruben Anthony, Jr., president of the Urban League of Greater Madison (ULGM). "The jobs created by this company are sustainable with full benefits, including company stock, generous paid time off, and health insurance. These are transformative opportunities. We are proud of this partnership and this city is fortunate to have an employer committed to growing locally and doing business the right way creating opportunities for so many."
Since the program launch in 2018, it trained 31 people. Of those, 84% (26 people) received job offers at Exact Sciences. Those interested in positions at the company can search a complete database of open jobs and apply online at http://careers.exactsciences.com.
Contact: Scott Larrivee, Exact Sciences, 608-287-9261, [email protected]
About Exact Sciences Corp.
Exact Sciences Corp. is a molecular diagnostics company working to deliver life-changing innovations in earlier cancer detection. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Now, Exact Sciences is investing in its product pipeline and collaborating with industry-leaders with the goal of taking on the world's deadliest cancers. For more information visit www.exactsciences.com.
Cologuard is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. A positive result may indicate the presence of colorectal cancer (CRC) or advanced adenoma (AA) and should be followed by diagnostic colonoscopy. Cologuard is indicated to screen adults of either sex, 50 years or older, who are at typical average-risk for CRC. Cologuard is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high risk individuals.
Cologuard is not for high risk individuals, including those with a history of colorectal cancer and advanced adenoma, a family history of colorectal cancer, IBD or certain hereditary syndromes. Positive Cologuard results should be referred to diagnostic colonoscopy. A negative Cologuard test result does not guarantee absence of cancer or advanced adenoma. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Cologuard performance when used for repeat testing has not been evaluated or established. Rx only.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate" or other comparable terms. All statements other than statements of historical facts included in this news release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales and marketing efforts, expectations concerning payer reimbursement and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance companies and other payers to cover our products and services and adequately reimburse us for such products and services; the amount and nature of competition from other cancer screening and diagnostic products and services; the effects of the adoption, modification or repeal of any law, rule, order, interpretation or policy relating to the healthcare system, including without limitation as a result of any judicial, executive or legislative action; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our ability to effectively utilize strategic partnerships, such as our Promotion Agreement with Pfizer, Inc., and acquisitions; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
SOURCE EXACT SCIENCES CORP